Pharmacokinetics: Metabolism, Excretion, Bioavailability & Half-Life
- Converts lipophilic drugs → more hydrophilic forms to enable removal.
- Principal site: liver (microsomal enzymes).
- Two phases:
- Phase I: functionalisation via cytochrome P450 → alters solubility/activity.
- Phase II: conjugation with polar molecule → highly water-soluble metabolite.
Hepatic First-Pass Effect
- All orally-taken drugs enter liver via hepatic portal vein before systemic circulation.
- Extensive metabolism here ↓ available dose.
- Example: Glycerol trinitrate – ≈96% destroyed on first pass.
- High first-pass → prefer non-oral routes (e.g., sublingual).
Excretion
- Removes drug/metabolites from body.
- Major route: kidneys (filtration → reabsorption → secretion → urine).
- Other routes: bile/faeces, breath, saliva, sweat, breast milk.
Drug Clearance
- Sum of metabolism + excretion rates across all organs.
- Determines overall elimination.
Dose Adjustment in Impaired Function
- Hepatic disease ↓ metabolism → prolongs drug action.
- Renal disease ↓ excretion.
- Usual response: reduce dose and/or extend dosing interval.
Bioavailability (F)
- Fraction of administered dose reaching systemic circulation unchanged.
- Influenced by: absorption losses + hepatic first-pass.
- Non-oral routes (IV, sublingual, buccal, rectal, inhalation) bypass first-pass → ≈100% F.
- Example: Morphine
• IV: 100% F → give 10mg for 10mg target dose.
• Oral: 30% F → need ≈30mg to deliver same 10mg systemically.
Drug Half-Life (t1/2)
- Time for plasma concentration to fall by 50%.
- Example: 100mg⋅L−1→50mg⋅L−1 in 4h ⇒ t1/2=4h.
- Elimination usually complete after 4–5t1/2.
- Overdose ↑ initial concentration → more half-lives needed.
Steady State & Dosing
- Goal: maintain plasma level ≥ minimum effective concentration.
- Steady state reached after 4–5t1/2 with regular dosing.
- Long t1/2 (e.g., 48h): days to steady state (e.g., antidepressants).
- Short t1/2 (e.g., 2h): steady state within hours.